The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



IPO | Merged

Total Raised






About Regado Biosciences

Regado Biosciences, a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. The Company provides REG1 that is used in patients suffering from acute coronary syndrome that undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention.

Regado Biosciences Headquarter Location

120 Mountainview Blvd.

Basking Ridge, New Jersey, 07920,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Regado Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Regado Biosciences is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Regado Biosciences Patents

Regado Biosciences has filed 9 patents.

patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Coagulation system, Coagulopathies, Glycoproteins, Proteins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Coagulation system, Coagulopathies, Glycoproteins, Proteins



Latest Regado Biosciences News

Colchicine fails to reduce mechanical ventilation, 28-day mortality in COVID-19 pneumonia

Jan 12, 2022

Disclosures: This study was funded by the Population Health Research Institute and Fundacion ECLA. Bhatt reports grants from Amarin, AstraZeneca, Forest Laboratories, Bristol Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company, Roche, Pfizer, Ischemix, Cardax, Amgen, Eli Lilly & Co., Chiesi, Ironwood, PhaseBio, Idorsia, Synaptic, Abbott, Regeneron, Novo Nordisk, Fractyl, Cereno Scientific, Afimmune, Ferring Pharmaceuticals, Contego Medical, CellProthera, Lexicon, MyoKardia, Owkin, HLS Therapeutics, Janssen, 89Bio, Garmin, PLxPharma, and Novartis; personal fees from Duke Clinical Research Institute, the Mayo Clinic, the Population Health Research Institute, the American College of Cardiology, Belvoir Publications, Slack Publications, WebMD, Elsevier, the Society of Cardiovascular Patient Care, HMP Global, Harvard Clinical Research Institute, the Journal of the American College of Cardiology, the American Heart Association, the Cleveland Clinic, Mount Sinai School of Medicine, TobeSoft, Boehringer Ingelheim, Bayer, Medtelligence/ReachMD, CSL Behring, MJH Life Sciences, Level Ex, K2P, and the Canadian Medical and Surgical Knowledge Translation Research Group; serving as a site coinvestigator for Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical, Philips, and Svelte; performing unfunded research for FlowCo, Merck, and Takeda; serving on an advisory board for Medscape Cardiology and Regado Biosciences; serving as a deputy editor for Clinical Cardiology and on the publications committee for VA CART Research and Publications Committee; and serving on the board of directors for Boston VA Research Institute. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Colchicine fails to significantly reduce mechanical ventilation or 28-day mortality in hospitalized patients with COVID-19 pneumonia, compared with usual care, according to data published in JAMA Network Open. “Colchicine is a relatively safe, and in most parts of the world, inexpensive anti-inflammatory drug with which doctors everywhere are familiar,” Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, of Brigham and Women’s Hospital and Harvard Medical School, in Boston, told Healio. “Those attributes of colchicine led to this trial in patients hospitalized with COVID-19. If it had been positive, it would have been an easy to implement therapy for COVID.” Colchicine fails to significantly reduce mechanical ventilation or 28-day mortality in hospitalized patients with COVID-19 pneumonia, compared with usual care, according to data derived from Diaz R, et al. JAMA Netw Open. 2021;doi:10.1001/jamanetworkopen.2021.41328. To analyze the efficacy of colchicine among hospitalized patients with COVID-19 pneumonia , Bhatt and colleagues conducted the COLOCOVID study, a multicenter, open-label, randomized clinical trial. A total of 1,279 adults hospitalized with confirmed or suspected COVID-19 — with severe acute respiratory syndrome characterized by shortness of breath or typical or atypical pneumonia on imaging, or oxygen desaturation — were randomized 1:1 to receive usual care or usual care plus colchicine. Patients with clear indications or contraindications for colchicine , chronic kidney disease or a negative reverse transcription-polymerase chain reaction test for COVID-19 prior to randomization were excluded. In all, 639 patients were assigned to the usual care group, while 640 patients received colchicine. Corticosteroids were used in 1,171 participants, or 91.5% of the total study population. Deepak L. Bhatt Colchicine was administered orally in a loading dose of 1.5 mg immediately after randomization, followed by a 0.5 mg dose within 2 hours of the initial dose and additional 0.5 mg doses twice a day for 14 days or discharge. The trial was conducted from April 17, 2020, to March 28, 2021. Participants were followed for 28 days, with analysis conducted from June 20, 2021, to July 25, 2021. Main outcomes included new requirement for mechanical ventilation or death evaluated at 28 days, with death at 28 days serving as a second coprimary outcome. According to the researchers, mechanical ventilation or 28-day death occurred in 25% of patients in the colchicine group, compared with 28.8% in the usual care group (HR = 0.83; 95% CI, 0.67-1.02). Meanwhile, the second coprimary outcome, 28-day death, occurred in 20.5% of those who received colchicine, compared with 22.2% in those who received usual care (HR = 0.88; 95% CI, 0.7-1.12). Diarrhea was the most frequent adverse effect of colchicine, reported in 11.3% of patients in the group. “The data from this trial do not show any significant benefit of colchicine in COVID-19 patients, and the drug should not be used for that purpose at this time without further larger, definitive randomized trials that show clear benefit,” Bhatt said. “There appeared to be a possible signal of a modest degree of benefit that would need to be confirmed in a larger, adequately sized trial of either colchicine or maybe other drugs that have anti-inflammatory effects but have been repurposed for potential use in COVID-19 patients,” he added. “Hopefully, such trials will occur, but it may be challenging to find funding to conduct trials that are large enough to be definitive.” Read more about

  • When was Regado Biosciences founded?

    Regado Biosciences was founded in 2003.

  • Where is Regado Biosciences's headquarters?

    Regado Biosciences's headquarters is located at 120 Mountainview Blvd., Basking Ridge.

  • What is Regado Biosciences's latest funding round?

    Regado Biosciences's latest funding round is IPO.

  • How much did Regado Biosciences raise?

    Regado Biosciences raised a total of $173.63M.

  • Who are the investors of Regado Biosciences?

    Investors of Regado Biosciences include Aurora Funds, Domain Associates, Quaker BioVentures, Andera Partners, Caxton Advantage Life Sciences Fund and 8 more.

  • Who are Regado Biosciences's competitors?

    Competitors of Regado Biosciences include Portola Pharmaceuticals, Athersys, Iconic Therapeutics, Threshold Pharmaceuticals, Dendreon and 14 more.

You May Also Like

Altair Therapeutics

Altair Therapeutics is a biotechnology company focused on the discovery, development and commercialization of antisense drugs for respiratory conditions.

Chroma Therapeutics

Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.


REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

Alice Therapeutics

Alice Therapeutics is a biotechnology company.

Decimmune Therapeutics

DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's approach is based on the discovery of an innate IgM-mediated auto-immune pathway that is triggered by vascular injury in conditions such as diabetic nephropathy, sickle cell disease, and myocardial infarction. This pathway, dubbed N2, can initiate a cascade of tissue damaging events leading to loss of organ function.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.